This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Taro Pharmaceutical (TARO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug
by Zacks Equity Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -20.11% and -28.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Sage Therapeutics (SAGE) Ahead of Earnings?
by Zacks Equity Research
Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
by Zacks Equity Research
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.
Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval
by Zacks Equity Research
Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -8.28% and -19.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
Sage Stock Declines on Late-Stage Depression Study Data
by Zacks Equity Research
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.
Is the Options Market Predicting a Spike in Sage Therapeutics (SAGE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.
Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.
Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate
by Zacks Equity Research
Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders
by Zacks Equity Research
Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 17.17% and -18.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.
Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study
by Zacks Equity Research
Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.
Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports fourth-quarter earnings.
Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More
by Zacks Equity Research
Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.
Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies
by Zacks Equity Research
Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.